Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.96), $0.86 worse than the analyst estimate of ($1.10). Revenue for the quarter came in at $0 versus the consensus estimate of $8.54 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.